Please select the option that best describes you:
What dose and formulation of GnRH agonist do you use for ovarian suppression in young breast cancer patients?
Do you use a q4 week or q12 week formulation? If you use both in your practice, what factors into your decision making for either one?
Answer from: Medical Oncologist at Academic Institution
Available data is largely with the monthly formulation. I don't have a strong preference for which LHRH agent (though some payers might). The q12-week depot formulation may not maintain full suppression for younger patients. Here is my pragmatic strategy
Start with monthly (q4 week). If not toler...
Sign in or Register to read more